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http://dx.doi.org/10.1016/j.stemcr.2016.09.008SUMMARYThe transition from hemogenic endothelial cells (HECs) to hematopoietic stem/progenitor cells (HS/PCs), or endothelial to hematopoi-
etic transition (EHT), is a critical step during hematopoiesis. However, little is known about the molecular determinants of HECs due to
the challenge in defining HECs. We report here the generation of GATA2w/eGFP reporter in human embryonic stem cells (hESCs) to mark
cells expressing GATA2, a critical gene for EHT. We show that during differentiation, functional HECs are almost exclusively GATA2/
eGFP+. We then constructed a regulatory network for HEC determination and also identified a panel of positive or negative surface
markers for discriminating HECs from non-hemogenic ECs. Among them, ITGB3 (CD61) precisely labeled HECs both in hESC differen-
tiation and embryonic day 10 mouse embryos. These results not only identify a reliable marker for defining HECs, but also establish a
robust platform for dissecting hematopoiesis in vitro, which might lead to the generation of HSCs in vitro.INTRODUCTION
Differentiation of functional hematopoietic stem and pro-
genitor cells (HS/PCs) from human pluripotent stem cells
(hPSCs) provides a unique source of therapeutic cells for
blood diseases and thus generates wide research interests
in the field (Daley and Lux, 2014; Liu et al., 2015; Singbrant
et al., 2015). Indeed, significant progress have been made
on how to drive hPSC differentiation toward different
blood lineages (Doulatov et al., 2013; Kennedy et al.,
2012; Vodyanik et al., 2005; Wang et al., 2012; Woods
et al., 2011). However, HS/PCs derived fromhPSCs through
current differentiation protocols showed very limited
engraftment and hematopoietic reconstitution in vivo
(Doulatov et al., 2013; Wang et al., 2005; Woods et al.,
2011). These findings indicate that the in vitro conditions
for driving blood differentiation do not fully recapitulate
themechanisms of hematopoiesis in vivo. During develop-
ment, numerous studies using different models such as
zebrafish andmouse embryos have shown that hematopoi-
etic stem cells (HSCs) emerge directly from a unique
endothelial population, the hemogenic endothelial cells
(HECs), through a special process called endothelial to he-
matopoietic transition (EHT) (Bertrand et al., 2010; Boisset854 Stem Cell Reports j Vol. 7 j 854–868 j November 8, 2016 j ª 2016 The
This is an open access article under the CC BY-NC-ND license (http://creativet al., 2010; Tavian et al., 2010). During EHT, cells with
endothelium phenotype gradually acquire hematopoietic
morphology and characteristics. The EHT process has also
been detected during the in vitro blood differentiation of
human PSCs (Eilken et al., 2009; Rafii et al., 2013). There-
fore, systematic analysis and comparison of the EHT pro-
cess in vivo and in vitro at the molecular level might aid
the generation of functional HS/PCs from hPSCs.
To date, a number of key transcription factors (TFs) and
signaling pathways that control EHT have been identified
in mouse and zebrafish (Chanda et al., 2013; Clements
and Traver, 2013; Kissa and Herbomel, 2010; Wang et al.,
2013; Wei et al., 2014). For instance, in mouse embryo,
Runx1 is highly expressed in both HECs and HSCs and
plays essential roles in EHT (Chen et al., 2009). GATA2 is
another factor that is known to be critical for hematopoie-
sis (Rodrigues et al., 2012; Vicente et al., 2012). Mouse em-
bryo lacking Gata2 died at an early stage due to the severe
anemia (Gao et al., 2013; Lim et al., 2012; Ling et al., 2004;
Tsai et al., 1994). Notably, mouse HECs without Gata2
failed to produce long-term repopulating HSCs due to an
impaired EHT (de Pater et al., 2013). We have also demon-
strated that human embryonic stem cells (hESCs) with
GATA2 deficiency exhibited a reduced EHT during bloodAuthor(s).
ecommons.org/licenses/by-nc-nd/4.0/).
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differentiation (Huang et al., 2015). These reports suggest
that the critical role of GATA2 in regulating EHT is
conserved in different species and systems. In addition to
the EHT process, TFs also play essential roles in deter-
mining the normal function of HS/PCs. For example, over-
expression of Hoxb4 could enhance the engraftment of
hematopoietic progenitor cells (HPCs) derived frommouse
ESCs (Kyba et al., 2002). However, HOXB4 did not show a
similar function in hESC-derived HPCs (Wang et al., 2005),
indicating that different TFs need be identified for human
cells. Indeed, many other factors such as HOXA9 ERG,
RORA, SOX4, and MYB have been tested for promoting
engraftment of HS/PCs generated in vitro. However, none
of these factors were able to mediate long-term engraft-
ment of these in vitro generated human HS/PCs (Doulatov
et al., 2013; Ramos-Mejia et al., 2014; Vanhee et al., 2015).
Another approach to generate HS/PCs in vitro is through
direct specification of functional HECs into HS/PCs.
Indeed, it has been shown that endothelial cells isolated
from the aorta gonad mesonephros (AGM) region at em-
bryonic day 10.5 (E10.5) to E11.5 mouse embryos effi-
ciently generated HPCs in vitro (Li et al., 2013). However,
how to precisely discriminate the functional HECs from
non-hemogenic ECs remains challenging. The inaccessi-
bility of HECs largely hampers the further understanding
of their molecular determinants during hematopoiesis.
To further investigate themolecular program involved in
HEC determination during human hematopoiesis, we
generated a GATA2/eGFP reporter in H1 hESCs through
gene targeting, referred as GATA2w/eGFP hESCs. Based on
an hPSC blood differentiation protocol in co-culturing
with OP9 (Vodyanik et al., 2005), we show that GATA2/
eGFP expression almost exclusively marks the functional
HECs with the potential to produce CD34+CD43+ HPCs.
We then separated HECs from non-hemogenic ECs in
hESC differentiation by cell sorting based on GATA2/
eGFP expression. Through further comparative analysis of
whole-transcriptome data on GATA2/eGFP+ HECs andFigure 1. Targeting of eGFP to the GATA2 Locus in H1 hESCs
(A) Scheme of the GATA2 locus targeting strategy. Partial GATA2 loc
vector below it. Homologous recombination aided by TALEN result
(GATA2eGFPPuro). Removal of PGK-Puro cassette with Cre recombinase
cassette are labeled with P1 and P2. Probe 1, eGFP probe; Probe 2, 3
(B) PCR analysis (with P1 and P2) of modified H1 hESCs. A 0.3-kb
fragments represent the insertion cassette before and after PGK-Puro
(C and D) Southern blot analysis of the GATA2eGFP H1 hESCs with pro
5.12-kb fragments corresponding to GATA2 WT and modified allele.
(E) Flow gating strategy of eGFP+ and eGFP cells from the TRA-1-85
(F) Real-time qPCR analysis of GATA2 expression in the sorted cells as
three independent experiments, in this and subsequent figures, unle
(G–I) Gating strategy of eGFP+ and eGFP cells from BMP4 (50 ng/mL)
western blot (I) (by FLAG antibody) examination of GATA2 expressio
856 Stem Cell Reports j Vol. 7 j 854–868 j November 8, 2016GATA2/eGFP non-hemogenic ECs, we constructed a
regulatory network positive or negative for hemogenic
endothelial (HE) determination. Moreover, we identified
a list of differentially expressed cell-surface markers be-
tween GATA2/eGFP+ HECs andGATA2/eGFP ECs. Among
them, CD61 precisely labeled functional HECs not only in
hESC differentiation but also in yolk sac (YS) or AGM
region at E10.0 in mouse embryos. The identification of
CD61 provides a reliable marker for accessing and enrich-
ing HECs, whichmight greatly facilitate the understanding
of HEC determination both in vivo and in vitro.RESULTS
Generation of H1 hESC-GATA2w/eGFP Cell Line
To target an eGFP into GATA2 locus in human ESCs, we
designed a pair of TALENs (transcription activator-like
effector nucleases) that could target GATA2 with high
specificity and activity (Cermak et al., 2011; Huang et al.,
2015) (Figures S1A–S1D). GATA2 TALENs along with the
linearized GATA2/eGFP targeting vector were then electro-
porated into H1 hESCs for gene editing (Figure 1A). Further
through drug selection, the correctly targeted colonies
were chosen and verified by PCR with indicated primers
(Table S1). Subsequently, the drug-resistant gene was
removed with Cre recombinase to obtain the final targeted
H1-GATA2w/eGFP, which was further verified by both PCR
(Figure 1B) and Southern bot (Figures 1C and 1D). The final
H1-GATA2w/eGFP hESCs maintained normal phenotype as
do typical hESCs under undifferentiated culture conditions
(data not shown). To examine the correlation between
eGFP and GATA2 expression, we employed OP9 co-culture
for blood differentiation (Vodyanik et al., 2006). As shown
in Figure 1E, we detected a significant cell population ex-
pressing eGFP at day 10 of H1-GATA2w/eGFP/OP9 co-culture
(Figure 1E). The eGFP+ cells showed a much higher level
of GATA2 expression while the eGFP cells were GATA2us with BglII restriction sites is shown (upper) with the targeting
s in the replacement of stop codon with FLAG-2A-eGFP cassette
yields final GATA2eGFP locus (lower). PCR primers flanking insertion
0 external probe.
fragment represents the WT GATA2 allele. The 3.40-kb and 1.1-kb
cassette, respectively.
bes 1 and 2. The heterozygous cell line displays both 4.10-kb and
+ fraction at day 10 of H1-GATA2w/eGFP/OP9 co-culture.
in (E). Error bars represent mean + SEM of the mean of samples from
ss otherwise indicated.
disposed H1-GATA2w/eGFP cells at day 5 (G). Real-time qPCR (H) and
n in each population.
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Figure 2. eGFP Expression Marks the HECs and HPCs
(A) FACS analysis of eGFP, CD34, CD31, and CD43 during the H1-GATA2w/eGFP/OP9 co-culture at indicated time points.
(B) Left and middle: isolation of eGFP+ and eGFP cells in CD34+CD31+CD43 fraction from day 8 of H1-GATA2w/eGFP/OP9 co-culture; right:
FACS analysis of CD34+CD43+ HPC percentage in CD34+ cells. Sorted cells from the middle were co-cultured on OP9 for 2 days before colony-
forming assay. Error bars represent mean + SEM of the mean of samples from four independent experiments. Asterisks indicate statistical
significance determined by t test: ***p < 0.001.
(C) Endothelial potential of eGFP+ and eGFP cells from CD34+CD31+CD43 fraction. Phase contrast, DiI-Ac-LDL uptake, and capillary
structure are shown from left to right. Scale bars represent 100 mm in this and subsequent figures unless otherwise indicated.
(D) FACS analysis of CD309 and CD144 expression on the eGFP+ and eGFP cells in CD34+CD31+CD43 fraction.
(legend continued on next page)
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negative (Figure 1F), indicating that eGFP expression was
highly related to GATA2 expression during differentiation.
In addition, we also examined H1-GATA2w/eGFP in a bone
morphogenetic protein 4 (BMP4)-induced differentiation
condition. BMP4 has been reported to induce GATA2
expression (Maeno et al., 1996), hence we examined the
GATA2 and eGFP expression in H1-GATA2w/eGFP with
BMP4 treatment for 5 days. Through both real-time qPCR
and western blot, we further confirmed the strict correla-
tion between eGFP andGATA2 expression in another differ-
entiation system (Figures 1G–1I). Altogether, we demon-
strated that the eGFP reporter targeted in GATA2 locus in
hESCs could be used to mark the endogenous expression
of GATA2.
GATA2/eGFP Expression Defines HECs and HPCs in
hESC Differentiation
Since GATA2 is a pivotal factor for hematopoiesis, we then
analyzed hematopoietic potential on GATA2/eGFP+ and
GATA2/eGFP populations during blood differentiation.
GATA2/eGFP+ cells were detected at the time when
CD31+ cells, a previously known HEC population (Naka-
jima-Takagi et al., 2013) appeared, preceding the formation
of CD43+ population, theHPCs identified in hESC differen-
tiation (Vodyanik et al., 2006) (Figure 2A). However, the
previously recognized HECs with the phenotype of
CD34+CD31+CD43 contained both GATA2/eGFP+ and
GATA2/eGFP populations (Figure 2B). Upon sorting and
replating onto OP9 stromal cells, only the GATA2/eGFP+
population could further give rise to CD34+CD43+ HPCs
(Figure 2B). To further strengthen this finding, we also
examined the hematopoietic potential of GATA2/eGFP-
positive or -negative cells in a different co-culturing system.
Upon co-culturing with another stromal cell, AGM-S3 (Xu
et al., 1998), we found again that it was the GATA2/eGFP+,
not the GATA2/eGFP cells that could efficiently produce
HPCs (Figure S2A). In contrast, both GATA2/eGFP+ and
GATA2/eGFP cells were able to produce monolayer endo-
thelial cells with typical endothelial characteristics such as
acetylated low-density lipoprotein (Ac-LDL) uptake and
capillary structure formation (Figure 2C). In addition,
both GATA2/eGFP+ and GATA2/eGFP cells highly express
typical endothelial markers such as CD309 and CD144
(Figure 2D). These data demonstrate that at the early
stage of blood differentiation, GATA2/eGFP expression
marked the functional HECs and could be used to discrim-
inate HECs from non-hemogenic endothelial cells (ECs).(E–G) FACS analysis of eGFP expression in CD34+CD43+ cell fraction at
CD34+CD43+, CD34+CD43 cells (F) and eGFP+, eGFP cells (G) at day 1
M, macrophage; GM, G and M; Mix, E, G, and M.
(H) Phase contrast, cytospin, and FACS analysis of CFU-E.
(I) Left: real-time qPCR analysis of HBB, HBE, and HBG1 expression i
858 Stem Cell Reports j Vol. 7 j 854–868 j November 8, 2016Furthermore, we showed that almost all CD34+CD43+
HPCs derived fromHECs are alsoGATA2/eGFP+ (Figure 2E).
As expected, these CD34+CD43+GATA2/eGFP+ HPCs were
able to form different types of colony-forming unit (CFU)
(Figures 2F, S2B, and S2C). Conversely, cell populations
sorted by GATA2/eGFP+ from OP9 co-culture exhibited
HPCpotential in forming different CFUs (Figure 2G).More-
over, we showed that the CFU-erythrocyte derived from
GATA2/eGFP+ HECs and HPCs express both embryonic
and adult globins, such as HBE, HBG1, and HBB (Figures
2H and 2I). This observation suggests that GATA2/eGFP+
HECs could give rise to HPCs representing both primitive
and definitive hematopoietic systems. Taking these data
together, we demonstrated that GATA2/eGFP expression
labels both HECs and HPCs during blood differentiation
of hPSCs.
Molecular Signature of GATA2/eGFP+ HECs
We then analyzed the whole-genome transcriptome on
GATA2/eGFP+ HECs and GATA2/eGFP ECs during hESC
blood differentiation. GATA2/eGFP+ HECs and GATA2/
eGFP ECs labeled by CD34+CD31+CD43 were sorted at
day 8 of OP9 co-culture and analyzed by RNA sequencing
(RNA-seq). Consistent with the phenotype described
above, the biological functions of genes upregulated in
GATA2/eGFP+HECs aremore related to hematopoiesis (Fig-
ure 3A). In contrast, genes upregulated in GATA2/eGFP
ECs are enriched in endothelium development and angio-
genesis (Figure 3A). The critical genes known for normal
function of HSC or HSC niche such as ALDH1A1, GFI1,
and MYB were enriched in the eGFP+ cells (Ghiaur et al.,
2013) (Figure 3C), whereas vital endothelium genes such
as SOX17 and NT5E (CD73) were downregulated in the
eGFP+ cells (Figure 3B) (Choi et al., 2012; Nakajima-Takagi
et al., 2013). Genes known for pan-endothelial, arterial,
venous, and lymphatic endotheliumwere highly expressed
in GATA2/eGFP ECs (Figure 3D) (Table S3). Notably, some
genes related to heart development such as TBX3 (Bakker
et al., 2008) and TBX18 (Cai et al., 2008) were also ex-
pressed by GATA2-positive cells (Figure 3A). This may be
attributed to the elevated expression level of certain
GATA factors, GATA6 (Zhao et al., 2008) for example, in
the GATA2/eGFP+ population, and these GATA factors are
known to be involved and important in cardiac system
development. However, factors involved in cardiac devel-
opment may also be regulated by GATA2 during hemato-
poiesis, and this needs to be evaluated in future studies.day 10 of H1-GATA2w/eGFP/OP9 co-culture (E). CFU assay of sorted
0 of H1-GATA2w/eGFP/OP9 co-culture. E, erythrocyte; G, granulocyte;
n CFU-E. Right: FACS analysis of HBB expression in CFU-E.
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Figure 3. Global Gene Expression Analysis of eGFP+ and eGFP Cells in CD34+CD31+CD43 Fraction by RNA-Seq
(A) Left: MA plot for eGFP+ (n = 2) and eGFP (n = 2) cells in CD34+CD31+CD43 cells from day 8 of H1-GATA2w/eGFP/OP9 co-culture. The
green and red dots represent 708 and 427 upregulated genes in the eGFP and eGFP+ cells, respectively (p < 0.05). Right: gene ontology
analysis of these upregulated genes.
(B) Top 50 genes downregulated and upregulated in the GFP+ cells compared with GFP cells (p < 0.05). Genes in red have been reported to
regulate the EHT process.
(legend continued on next page)
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We further identified TFs that were differentially ex-
pressed in GATA2/eGFP+ and GATA2/eGFP populations.
The highly expressed TFs in GATA2/eGFP+ HECs include
many well-known critical factors for EHTor HPC function,
such as GFI1, RUNX1, MYB, and SPI1. We then sought to
investigate whether these TFs form an inter-regulatory
network. Based on previously reported protein-protein
interaction or gene expression data, we generated an inter-
action network using the identified GATA2 positively or
negatively related TFs (Figure S3B). Notably, 92.1% of the
GATA2 negatively related TFs or 83.8% of GATA2 positively
related TFs fell into the regulatory interaction network,
indicating that these TFs are highly connected and inter-
regulated. Such a network would be valuable for further in-
vestigations on the molecular mechanism diversifying
HECs and non-hemogenic ECs during hematopoiesis.
CD61 Defines Hemogenic Potential Cells during hPSC
Differentiation
Identification of reliable cell-surface markers for HECs is
critical in enriching well-defined HEC populations for
either investigating the mechanism of EHT or developing
technologies for generation of HPCs in vitro. We then re-
analyzed RNA-seq data and identified differentially ex-
pressed surface markers between GATA2/eGFP+ HECs and
GATA2/eGFP ECs as shown in Figure 4A. The marker lists
includemany previously known surfacemarkers associated
with hematopoietic cells. For example, NT5E (CD73) was
upregulated in the GATA2/eGFP ECs but not in the
GATA2/eGFP+ HECs, which is consistent with previously
reported data (Choi et al., 2012). Other reported hemato-
poietic markers such as CD62P (SELP) (Nkambule et al.,
2015) and CD41 (ITGA2B) (Boisset et al., 2013) were upre-
gulated in GATA2/eGFP+ HECs (Figure 4A). We then
selected markers that were not extensively analyzed previ-
ously and validated them by fluorescence-activated cell
sorting (FACS). As shown in Figure 4B, CD226 and CD61
were highly expressed in GATA2/eGFP+ HECs while
CD200 preferably marked GATA2/eGFP ECs. Among
these markers, we were particularly interested in CD61, a
member of the integrin family. Integrins are known to be
critical in the regulation of cell adhesion, survival, and
migration (Schlaepfer et al., 1999). In the mouse system,
CD61 has been shown to be enriched in adult HSCs with
long-term repopulating potential (Umemoto et al., 2008).
However, whether CD61 associates with the HECs preced-
ing the formation of HS/PCs remains unclear. To analyze(C) Fold change of selected genes (associated with the HS/PC, the HS
compared with eGFP cells. *p < 0.05.
(D) Fold change of selected genes associated with pan-endothelial,
eGFP+ cells (q < 0.1). Error bars represent mean + SEM of the mean of
*p < 0.05.
860 Stem Cell Reports j Vol. 7 j 854–868 j November 8, 2016the hemogenic potential of CD61+ or CD61 ECs, we
sorted and replated them on the OP9 cells, a well-estab-
lished assay for identification of HECs (Choi et al., 2012).
We firstly showed that at day 8 of blood differentiation
with OP9 co-culture, CD61+ population is almost all
GATA2/eGFP+, while conversely, only part of the GATA2/
eGFP+ cells (nearly one-third) are CD61+ (Figure 4C), indi-
cating that CD61 marked a subset of the GATA2/eGFP+
population. However, GATA2/eGFP+CD61+ ECs produced
significantly more CD34+CD43+ HPCs than GATA2/
eGFP+CD61 cells upon sorting and replating onto OP9
for co-culture (Figure 4C). These data suggest that the
CD61 expression marked the HEC subset in the GATA2/
eGFP+ population. We also showed that these CD61+
HECs retain the potential to form a capillary structure of
typical ECs and thus are bipotent (Figure 4D). Since the
CD61 cells could also generate a certain number of
HPCs (Figure 4C), we asked whether it is possible that
some of these CD61 cells might transit into CD61+ later.
Indeed, upon replating onto OP9 cells for 1 day of co-cul-
ture, some CD34+CD31+CD43CD61 cells transited into
CD34+CD31+CD43CD61+ and then CD34+CD31+CD43+
CD61+ HPCs upon differentiation for another day (Fig-
ure S4A). In all, these data demonstrate that CD61 is a pos-
itive marker for HECs.
Since we have demonstrated the critical role of CD61 in
defining HECs using a hESC GATA2w/eGFP reporter, we
then examined whether it marks HECs in other wild-type
(WT) hPSCs. We thus analyzed the blood differentiation
of WT hESCs and human induced pluripotent stem cells
(hiPSCs), such as H1, H9, and UH1, by OP9 co-culture.
We showed that the previous known HEC population
defined by CD34+CD31+CD43 at day 8 of OP9 co-culture
contained both CD61+ and CD61 populations. CD61+
cells from H1, H9, or UH1 gave rise to a significant number
of CD34+CD43+ HPCs, while CD61 cells generated very
few CD34+CD43+ HPCs (Figures 4F and 4G). These data
demonstrated that CD61 defines a subset population
with hemogenic potential in previously identified
CD34+CD31+CD43 endothelium during hPSC blood dif-
ferentiation. Again, CD61-labeled HECs from WT H1
hESCs are bipotent and can produce typical capillary struc-
ture (Figure 4D).
Wewent on to analyze CD61 expression in CD34+CD43+
HPCs at a later stage during blood differentiation of hPSCs.
For the hESC line GATA2w/eGFP, we showed that almost
all CD34+CD43+ HPCs generated by OP9 co-culture wereC niche, and myeloid, lymphoid, and erythroid cells) in eGFP+ cells
arterial, venous, and lymphatic cells in eGFP cells compared with
samples from two independent experiments from the RNA-seq data.
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Figure 4. CD61 Expression Marks the HECs and HPCs in hPSC Differentiation
(A) Heatmaps of top differentially expressed cell-surface markers in the eGFP and eGFP+ cells in CD34+CD31+CD43 fraction from day 8 of
H1-GATA2w/eGFP/OP9 co-culture. NT5E in red has been reported to be involved in EHT.
(legend continued on next page)
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double positive for GATA2/eGFP and CD61 (Figure 4H).
Similarly, for WT hPSC lines H1, H9, and UH1, almost all
CD34+CD43+ HPCs were CD61+ (Figure 4I), indicating
that CD61 also served as a marker in defining HPCs.
Indeed, we showed that the CD61+ cell population gener-
ated a significant number of CFUs while CD61 cells failed
to produce CFUs (Figure 4J). Taking these data together, we
demonstrated that CD61 marked both HECs at an early
stage and HPCs at a late stage of hPSC differentiation.
CD61 Defines Functional HECs in Mouse Embryo
We then sought to examine whether CD61 defines HECs
in vivo in mouse embryo. We firstly examined CD61
expression in a cell population with the EC phenotype
defined as CD31+CD41CD45Ter119 from YS and
AGM regions at E10.0 (31–34 somite pairs) in mouse em-
bryos. We found that this previously recognized EC pop-
ulation could be fractionated into CD61high, CD61low,
and CD61 subpopulations. The ECs with different levels
of CD61 expression were then sorted and replated onto
the OP9 stromal cells for further characterization of he-
mogenic potential (Figure 5A). Upon OP9 co-culture for
3–4 days, only the CD61low population, regardless of
whether from YS or AGM region, could efficiently pro-
duce typical hemogenic colonies (up to 6.6 ± 2.4 per em-
bryo equivalent; Figures 5B and 5C). Upon further co-cul-
ture (8–9 days), the CD61low fraction, although not other
populations, showed robust cell expansion and genera-
tion of CD45+ hematopoietic cells (Figures 5B and 5C).
These data demonstrate that CD61low marks the subset
of HECs in CD31+CD41CD45Ter119 ECs in mouse
early embryo. We further showed that CD61low HECs
from mouse embryo are bipotent and can produce
typical vascular structure (Figures 5D and 5E). In all, we
demonstrate that the CD61low cells mark a small subset
of functional HECs with bipotency in mouse embryo,
and thus could be used to efficiently enrich and access
functional HECs (up to a dozen-fold) in vivo for further
study.(B) Expression pattern of GATA2/eGFP and selected markers (CD73, CD2
OP9 co-culture.
(C) CD34+CD43+ percentage of three sorted cell subpopulations after fu
of H1-GATA2w/eGFP/OP9 co-culture. Asterisks indicate statistical signi
(D) Endothelial potential of eGFP+ and eGFP cells in CD34+CD31+CD
Phase contrast, DiI-Ac-LDL uptake, and capillary structure are shown
(E) Real-time qPCR validation of CD61 expression in indicated subpopu
OP9 co-culture.
(F) Gating strategy of CD61+ and CD61 cell sorting from CD34+CD31+
(G–I) FACS analysis (G) of CD34+CD43+ HPC generation (% of CD34+
replated on OP9 for a further 2-day co-culture. Asterisks indicate stati
analysis of CD61 and eGFP expression in CD34+CD43+ HPC at day 10 of c
(J) CFU assay of sorted CD34+CD61+ and CD34+CD61 cells at day 10
862 Stem Cell Reports j Vol. 7 j 854–868 j November 8, 2016DISCUSSION
Hematopoiesis is a highly regulated process controlled by
the coordination of TFs and diverse signaling pathways.
Knowledge of the mechanisms that drive HSC develop-
ment is critical for generation of functional HSCs
in vitro using hPSC differentiation. To date, significant
progress has been made in understanding the regulation
of HSC development, as well as identification of cell-sur-
face markers defining hematopoietic cells at different
developmental stages and regions in animal models
(Choi et al., 2012; Kennedy et al., 2012; Wang et al.,
2013). However, information on human hematopoiesis
remains quite limited due to the inaccessibility of human
materials. Hematopoietic differentiation of hESCs in vitro
provides a valuable model for understanding human he-
matopoiesis. It has been known that the in vitro hemato-
poietic differentiation of hESCs follows the basic principle
of the in vivo embryonic hematopoiesis in mouse
(Chanda et al., 2013). For example, EHT has been observed
during differentiation of hESCs for the generation of HPCs
(Rafii et al., 2013). Our previous work also showed that the
role of GATA2, a critical factor for mouse hematopoiesis, is
conserved in a hESCmodel, as GATA2/ hESCs exhibited
a significant defect in EHT and then HPC generation
(Huang et al., 2015). In the current study, we extended
our previous work to generate and analyze the blood dif-
ferentiation of a hESC GATA2w/eGFP reporter cell line
in vitro. We show that both HECs capable of producing
HPCs and the generated HPCs are almost exclusively
GATA2/eGFP+ cells. These data further highlight the crit-
ical role of GATA2 in the regulation of hematopoiesis. It
is worth noting that a recent report showed that some
HPCs in mice are independent of GATA2, although the
HSCs were proved to be exclusively GATA2 expressing
(Kaimakis et al., 2016). Our previous work also showed
that GATA2/ hPSC-derived HPCs can produce a certain
number of CFUs in vitro (Huang et al., 2015). More
detailed analysis of GATA2+ HSCs and GATA2 HPCs is00, CD226, and CD61), in CD34+CD31+CD43 cells at day 8 of hESCs/
rther 2-day co-culture with OP9. Flow sorting was performed at day 8
ficance determined by t test: *p < 0.05.
43 fraction derived from H1-GATA2w/eGFP and H1/OP9 co-culture.
from left to right.
lations isolated from CD34+CD31+CD43 fraction at day 8 of hESCs/
CD43 fraction at day 8 of unmodified hESCs/OP9 co-culture.
cells) by H1, H9, and UH1. Cells were sorted as shown above and
stical significance determined by t test: *p < 0.05, **p < 0.01. FACS
o-culture of OP9 with H1-GATA2w/eGFP (H) and H1, H9, and UH1 (I).
of H1, H9, and UH1/OP9 co-culture, respectively.
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Figure 5. CD61 Labels the HECs in Mouse Embryo
(A) From left to right: picture of YS and AGM at E10 of mouse embryo, FACS analysis of CD61 expression in CD31+CD41CD45Ter119 cells,
and picture of typical hemogenic colony formed after co-culture with OP9 stromal cells (original magnification is 53).
(B and C) From left to right: hemogenic colony formation, CD45+ cell generation, and cell expansion in the co-culture of OP9 with the
CD61high, CD61low, and CD61 cells in CD31+CD41CD45Ter119 fraction isolated from E10 in YS (B) and AGM (C) regions, respectively. ee,
embryo equivalent. Error bars represent mean + SEM of the mean of samples from five independent experiments. Asterisks indicate
statistical significance determined by t test: **p < 0.01.
(D) Phase contrast of tube formation of the CD61high, CD61low, and CD61 cells in CD31+CD41CD45Ter119 fraction. The tubes were
stained by anti-CD31 antibody via immunohistochemistry and are indicated by the red arrows.
(E) Statistical analysis of tube formation per 100 cells. Error bars represent mean + SEM of the mean of samples from four independent
experiments.
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needed in future research to enable full understanding of
the role of GATA2 during hematopoiesis.
Nevertheless, given the advantage of GATA2/eGFP as a
reporter, we were able to discriminate HECs from non-he-
mogenic ECs in hESC hematopoietic differentiation. To
investigate the molecular determinants for HE, we
analyzed and compared the transcriptome of GATA2/
eGFP+ HECs and GATA2/eGFP ECs derived from hESCs.
A panel of TFs that are positive and negative for HECs or
ECs were identified in a human model (Figure S3A).
Many important TFs for hematopoiesis are relatively
conserved between human and mouse. For example, the
well-known TFs identified in mouse hematopoietic devel-
opment, such as GFl1, RUNX1, MYB, and SPI1, are more
highly expressed in GATA2/eGFP+ HECs than in GATA2/
eGFP ECs (Figure S3B). Future workmight need to investi-
gate in detail the individual role of each previously uniden-
tified TF in hematopoiesis using both human and mouse
models.
Reliable cell-surface markers in defining hematopoietic
cells with different potential are valuable in assessing
well-defined populations for further investigation. Cell-
surface markers are of particular significance for hPSC dif-
ferentiation, as the in vitro system lacks anatomical and
morphological information. To date, a few surface markers
have been identified in defining blood cells at different
stages of hESC/iPSC differentiation (Choi et al., 2012; Vo-
dyanik et al., 2006). For example, CD43 has been identified
as a marker for hPSC-derived HPCs with the potential to
form CFUs, thus providing an easy way to isolate HPCs
in vitro (Vodyanik et al., 2006). However, defining func-
tional HECs has been complex and challenging due to
the limitation of reliable surface markers. Our finding
that the HECs are almost exclusively GATA2/eGFP+ allows
us to identify reliable surface markers for functional HECs.
Indeed, we identified a panel of cell-surface markers that
differentially expressed between GATA2/eGFP+ HECs and
GATA2/eGFP ECs. The lists include some previously iden-
tified hematopoietic markers such as CD62P and CD41,
and many other unidentified ones. Among them, CD61
is of particular significance as it almost exclusively marked
the small portion of HECs capable of producing HPCs in
hPSC differentiation. Interestingly, almost all HPCs
generated from hPSC-derived HECs are also CD61+. In
addition, the CFU-Mix (also referred as GEMM) potential
cells were restricted in the CD61low cells in YS of E10mouse
embryo (Figure S5A), indicating that CD61low also labels
HPCs in mouse early embryo. In another report, Boisset
et al. (2013) also showed that the HSCs with transplanta-
tion potential are restricted in the CD61low fraction in
E11 AGM and the E11 placenta, while at a later stage, as
in the E12 YS and E14 fetal liver, transplantable
HSCs were found in both CD61 and CD61low fractions,864 Stem Cell Reports j Vol. 7 j 854–868 j November 8, 2016indicating that CD61 marks HSCs at the specific stage of
mouse embryo.
Another integrin, CD41, was also increased in GATA2/
GFP+ HECs. CD41 has been known as a marker to identify
HPCs from mouse embryo (Ferkowicz, 2003). However,
mouse HECs were defined as CD41 (CD31+CD41CD45
Ter119). Interestingly, CD61 is usually co-expressed with
CD41 in many different cell types. However, our findings
show that at an early stage of hematopoiesis both in vitro
and in vivo, CD61 is expressed independently of CD41 in
HECs. Indeed, hematopoietic cells isolated from E8 or
E10 mouse embryo exhibited significant differential
expression of CD61 and CD41 (Figures S5B and S5C). Simi-
larly, the expressions of CD41 and CD61 are not consistent
in hematopoietic cells differentiated from hPSCs in vitro
(Figures S4B and S4C). These data indicate that CD61 or
CD41 might act independently in certain cell types or
stages of hematopoiesis, but their exact roles and timing
need to be investigated further. Nonetheless, our finding
that CD61 is conservative in defining HECs both in vitro
for hPSC differentiation and in vivo formouse embryo pro-
vides valuable information on how to define and access
the bipotent HECs. It is noteworthy that the percentage
of HECs labeled by CD61 from either YS or AGM is very
low, varying between 2%and 10%of previously recognized
ECs (Figure 5A). Therefore, the identification of CD61
would allow dozen-fold enrichment for HECs and would
greatly facilitate future research in understanding the
mechanisms of HE determination and HSC generation
both in vitro and in vivo.EXPERIMENTAL PROCEDURES
All experiments were carried out in accordance with the guidelines
of the Human Subject Research Ethics Committee at Guangzhou
Institutes of Biomedicine and Health (GIBH), Chinese Academy
of Sciences (CAS), and all experimental protocols were approved
by the committee. Formal informed consent was obtained from
all subjects.
All animal experiments were carried out in accordance with the
Guide for the Care and Use of Laboratory Animals instructed by
the Institutional Animal Care and Use Committee of Guangzhou
Institutes of Biomedicine and Health (IACUC-GIBH) and all proto-
cols were approved by the committee.TALEN Targeting
The binding and cutting sites of GATA2 knockin TALENs are illus-
trated in Figure S1, and the TALENs were designed as previously
described (Huang et al., 2015). For donor construction, left and
right homology arms were cloned from genomic DNA of H1 cell
line about 1 kb upstream and downstream of the stop code, respec-
tively. A FLAG-2A-eGFP-loxP-PGK-puromycin-loxP cassette was
further inserted into the homology arms in the vector pUC57.
For targeting, constructed vector was initially linearized by EcoRI,
then 1 mg of the linearized vector was electroporated into 1 3 106
H1 cells with 2.5 mg of each TALEN plasmid. After the transfection,
cells were seeded on Matrigel-coated 6-well plates in the presence
of 10 mM Y-27632 (Sigma). Puromycin (0.5 mg/mL, Sigma) was
added to the medium to select positive clones 2 or 3 days later.
Drug-resistant clones were picked out and genomic DNA of these
clones was used for PCR verification of successful targeting. After
the verification, the targeted clones were expanded and further
transfected with 400 ng of Cre recombinase for every 1 3 106 cells
to remove the loxP flanked PGK-puromycin cassette, followed by
seeding in a single-cell state in the presence of Y-27632. When
the clones grew up, they were picked for further verifications by
genomic PCR and Southern blot.
The GFP reporter assay was performed as previously reported
(Huang et al., 2015). In brief, the GFP reporter was inserted with
the WT or mutant sequence of the TALENs binding and cutting
sites. The reporter was then electroporated into the 293T cells
with the TALENs for test. After 48 hr, the cells were digested and
examined for GFP fluorescence by FACS.
PCR and Southern Blot Verification
PCR reactions were performed with KOD-Plus enzyme (Toyobo)
according to the manufacturer’s instructions. For each reaction,
50–100 ng of genomic DNA templates were used. PCR primers P1
and P2 (shown in Figure 1A) were designed to amplify 2.50-kb or
1.10-kb products. The 2.50-kb product was obtained from cell line
with the loxP flanked PGK-puromycin cassette. After removal of
the cassette, the 1.10-kb product was produced as illustrated in Fig-
ure 1B. For Southern blot, the reactions were carried out according
to the manuals of DIG High Prime DNA Labeling and Detection
StarterKit II (Roche). Specifically, genomicDNAwasdigestedbyBglII
endonuclease, and probes about 1 kb in length were synthesized by
PCR reaction. The eGFP probe (probe 1) was used to verify the inte-
gration of a single copy of eGFP sequence in the genome, and the 30
external probe (probe 2) was used to identify the insertion in the
TALEN cutting site as designed. All primers are listed in Table S1.
hPSC Culture and Differentiation in Co-culture
The procedures of hESC (H1 andH9) and hiPSC (UH1) culture, and
OP9-based hematopoietic differentiation were carried out as
described previously (Huang et al., 2015). In particular, gene target-
ing was performed at passage 38 of the H1 ESC line. In addition,
CD34+CD31+CD43 HECs at day 8 of hESC/OP9 co-culture and
CD34+CD43+ HPCs at day 10 of hESCs/OP9 co-culture were sorted
for further analysis. Furthermore, for assessment of hemogenic po-
tential of HECs or HE subpopulation, cells sorted at day 8 of differ-
entiationwere replated ontoOP9 or AGM-S3 stromal cells for 1 or 2
further days of co-culture before analysis.
FACS Analysis and Cell Sorting
The detailed procedure is presented in Supplemental Experimental
Procedures.
CFU Assay
CFU assay of hESC-derived HPCs was conducted following the
manufacturer’s protocol H4435 (STEMCELL). For CFU assay of
mouse scored cells, cellswere plated in 0.9%methylcellulose-basedmedium supplemented with 15% fetal bovine serum, 2 mM gluta-
mine, 100 U/mL penicillin-streptomycin, 5% protein-free hybrid-
oma medium II, 200 mg/mL iron-saturated holo-transferrin, 1%
BSA, 0.45mMmonothioglycerol, 100 ng/mL recombinantmurine
stem cell factor (PeproTech), 10 ng/mL recombinant murine
interleukin-3, 10 ng/mL recombinant human interleukin-6, and
3 U/mL human erythropoietin. Colonies were scored based on
the morphological criteria.
Real-Time qPCR
The detailed procedure is presented in Supplemental Experimental
Procedures.
RNA-Seq
RNA-seq and subsequent data analysis were conducted as described
byHuang et al. (2015). In brief, total RNAwas isolatedwith aDirect-
zol RNAMiniPrep kit (Zymo Research) and sequencing libraries was
prepared with a TruSeq RNA Sample Prep Kit (Illumina) following
themanufacturer’s protocol. The sampleswere run on anMiSeq sys-
temwithMiSeq Reagent Kits v2 (50 cycles) (Illumina). In particular,
RNA-seq data were processed essentially as described by Hutchins
et al. (2015), reads were aligned to an index generated from the En-
sembl transcriptome version 74 (hg19) using RSEM (v1.2.19), Bow-
tie2 (v2.2.5), andnormalizedwithEDASeq (v2.2.0).Geneexpression
is expressed as ‘‘normalized tag count.’’ A threshold of at least 20
normalized tags in any condition was used to filter lowly expressed
transcripts. Differential expression was performed using DESeq2
(v1.8.1) and genes were considered significant if they had a Benja-
mini-Hochberg corrected p value (q value) <0.1 and had a fold-
change > 1.5. Gene ontology was performed using goseq (v1.20.0).
Other analyses were performed using glbase (Hutchins et al., 2014).
Endothelial Cell Culture and Assays
Endothelial cell-related assays, including endothelial cell culture,
DiI-Ac-LDL uptake, and capillary structure formation, were per-
formed as described previously (Huang et al., 2015). In brief, the
eGFP+ and eGFP cells in CD34+CD31+CD43 cells were sorted
from day 8 of H1-GATA2w/eGFP/OP9 co-culture. Specifically, the
DiI-Ac-LDL uptake assay was performed as per the manual’s in-
structions. FACS-sorted CD61high, CD61low, and CD61 cells in
the CD31+CD41CD45Ter119 fraction were cultured on an
OP9 stromal cell layer to detect the endothelial cell colony forma-
tion in the presence of 100 ng/mL vascular endothelial growth
factor. After 7 days, cultured cells were fixedwith 4%paraformalde-
hyde and the forming capacity of endothelial tubules was assessed
by immunostaining with anti-CD31 antibody (BD Pharmingen).
Immunohistochemistry was performed as described previously
(Lan et al., 2007).
Mice and YS/AGM Cell Preparation
The detailed procedure is presented in Supplemental Experimental
Procedures.
Co-culture of YS and AGM Cell with OP9
The detailed procedure is presented in Supplemental Experimental
Procedures.Stem Cell Reports j Vol. 7 j 854–868 j November 8, 2016 865
Western Blot
The detailed procedure is presented in Supplemental Experimental
Procedures.
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